Although IL‐6 is generally considered a pro‐inflammatory cytokine, systemic ablation of IL‐6 in mice leads to mature‐onset obesity and insulin resistance.[15] A recent study has shown that IL‐6 mediates anti‐inflammatory effects in macrophages by promoting higher expression of M2 phenotype‐associated genes.[16] However, given the pro‐inflammatory capacity of IL‐6, it may not represent a promising therapeutic target for obesity treatment. Here, IL6 is linked to obesity due to melanocortin 4 receptor deficiency.